Found: 6
Select item for more details and to access through your institution.
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 2, p. 358, doi. 10.1002/cam4.4451
- By:
- Publication type:
- Article
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams.
- Published in:
- Frontiers in Oncology, 2022, v. 11, p. 1, doi. 10.3389/fonc.2021.819127
- By:
- Publication type:
- Article
OAB-053: Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S38, doi. 10.1016/S2152-2650(21)02133-9
- By:
- Publication type:
- Article
Evaluating Race and Time to Transplantation in Multiple Myeloma: The Mount Sinai Hospital Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 7, p. 439, doi. 10.1016/j.clml.2021.02.003
- By:
- Publication type:
- Article
Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody.
- Published in:
- Cancer Management & Research, 2023, v. 15, p. 741, doi. 10.2147/CMAR.S372237
- By:
- Publication type:
- Article
Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States.
- Published in:
- EJHaem, 2023, v. 4, n. 4, p. 984, doi. 10.1002/jha2.739
- By:
- Publication type:
- Article